

## DAFTAR PUSTAKA

- Adami, R., & Bottai, D. (2022). Curcumin and neurological diseases. *Nutritional Neuroscience*, 25(3), 441–461.
- Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). *Molecular Biology of The Cell*.
- Also-Rallo, E., Alías, L., Martínez-Hernández, R., Caselles, L., Barceló, M. J., Baiget, M., Bernal, S., & Tizzano, E. F. (2011). Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. *European Journal of Human Genetics*, 19(10), 1059–1065.
- Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. *Molecular Pharmaceutics*, 4(6), 807–818.
- Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021). Oxidative stress in cancer cell metabolism. *Antioxidants (Basel, Switzerland)*, 10(5), 642.
- Arnold, W. D., Kassar, D., & Kissel, J. T. (2015). Spinal muscular atrophy: diagnosis and management in a new therapeutic era. *Muscle & Nerve*, 51(2), 157–167.
- Aydin, S. (2015). A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. *Peptides*, 72, 4–15.
- Bagheri, H., Ghasemi, F., Barreto, G. E., Rafiee, R., Sathyapalan, T., & Sahebkar, A. (2020). Effects of curcumin on mitochondria in neurodegenerative diseases. *BioFactors (Oxford, England)*, 46(1), 5–20.
- Bemanalizadeh, M., Heidary, L., Dakkali, M. S., Hadizadeh, S., Ahmadbeigi, N., Heidari, M., Zamani, G., Ashrafi, M., & Mansouri, V. (2025). Combination therapies in spinal muscular atrophy: a systematic review. *European Journal of Pediatrics*, 184(9), 583.
- Berger, A., Mayr, J. A., Meierhofer, D., Fötschl, U., Bittner, R., Budka, H., Grethen, C., Huemer, M., Kofler, B., & Sperl, W. (2003). Severe depletion of mitochondrial DNA in spinal muscular atrophy. *Acta Neuropathologica*, 105(3), 245–251.
- Bora-Tatar, G., & Erdem-Yurter, H. (2014). Investigations of curcumin and resveratrol on neurite outgrowth: perspectives on spinal muscular atrophy. *BioMed Research International*, 2014, 709108.
- Chazotte, B. (2011). Labeling mitochondria with MitoTracker dyes. *Cold Spring Harbor Protocols*, 2011(8), 990–992.
- Chen, C., Zhang, J., Xue, C., Liu, D., & Li, S. (2025). Advances in the potential role and mechanism of fibroblasts in spinal muscular atrophy. *Cell Biochemistry and Function*, 43(9), e70118.
- Chen, T.-H. (2020). New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand? *International Journal of Molecular Sciences*, 21(9), 3297.
- Chojnacki, A. K., Navaneetha Krishnan, S., Jijon, H., Shutt, T. E., Colarusso, P., & McKay, D. M. (2023). Tissue imaging reveals disruption of epithelial

- mitochondrial networks and loss of mitochondria-associated cytochrome-C in inflamed human and murine colon. *Mitochondrion*, 68, 44–59.
- Coovert, D. D., Le, T. T., McAndrew, P. E., Strasswimmer, J., Crawford, T. O., Mendell, J. R., Coulson, S. E., Androphy, E. J., Prior, T. W., & Burghes, A. H. (1997). The survival motor neuron protein in spinal muscular atrophy. *Human Molecular Genetics*, 6(8), 1205–1214.
- Dayangac-Erden, D., Bora-Tatar, G., Dalkara, S., Demir, A. S., & Erdem-Yurter, H. (2011). Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics. *Archives of Medical Science*, 7(2), 230–234.
- de Oliveira, M. R., Nabavi, S. F., Manayi, A., Daglia, M., Hajheydari, Z., & Nabavi, S. M. (2016). Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view. *Biochimica et Biophysica Acta*, 1860(4), 727–745.
- Dick, M. K., Miao, J. H., & Limaiem, F. (2025). Histology, fibroblast. In *StatPearls*. StatPearls Publishing.
- Dong, L., & Neuzil, J. (2019). Targeting mitochondria as an anticancer strategy. *Cancer Communications (London, England)*, 39(1), 63.
- Dubowitz, V. (1999). Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. *European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society*, 3(2), 49–51.
- Dumas, S. A., Villalón, E., Bergman, E. M., Wilson, K. J., Marugan, J. J., Lorson, C. L., & Burnett, B. G. (2022). A combinatorial approach increases SMN level in SMA model mice. *Human Molecular Genetics*, 31(17), 2989–3000.
- Duplancic, R., & Kero, D. (2021). Novel approach for quantification of multiple immunofluorescent signals using histograms and 2D plot profiling of whole-section panoramic images. *Scientific Reports*, 11(1), 8619.
- Ebert, A. D., & Svendsen, C. N. (2010). Stem cell model of spinal muscular atrophy. *Archives of Neurology*, 67(6), 665–669.
- Ebert, A. D., Yu, J., Rose, F. F., Jr, Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature*, 457(7227), 277–280.
- Evans, M. C., Cherry, J. J., & Androphy, E. J. (2011). Differential regulation of the SMN2 gene by individual HDAC proteins. *Biochemical and Biophysical Research Communications*, 414(1), 25–30.
- Farrar, M. A., & Kiernan, M. C. (2015). The genetics of spinal muscular atrophy: Progress and challenges. *Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics*, 12(2), 290–302.
- Feng, D., Cheng, Y., Meng, Y., Zou, L., Huang, S., & Xie, J. (2015). Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript. *Genes & Nutrition*, 10(6), 40.
- Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., ... ENDEAR Study Group.

- (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *The New England Journal of Medicine*, 377(18), 1723–1732.
- Fuller, H. R., Mandefro, B., Shirran, S. L., Gross, A. R., Kaus, A. S., Botting, C. H., Morris, G. E., & Sareen, D. (2015). Spinal muscular atrophy patient iPSC-derived motor neurons have reduced expression of proteins important in neuronal development. *Frontiers in Cellular Neuroscience*, 9, 506.
- Fung, T. S., Chakrabarti, R., & Higgs, H. N. (2023). The multiple links between actin and mitochondria. *Nature Reviews. Molecular Cell Biology*, 24(9), 651–667.
- Gallardo-Villagrán, M., Paulus, L., Leger, D. Y., Therrien, B., & Liagre, B. (2022). Dimethyl sulfoxide: A bio-friendly or bio-hazard chemical? The effect of DMSO in human fibroblast-like synoviocytes. *Molecules (Basel, Switzerland)*, 27(14), 4472.
- Gediya, P., Parikh, P. K., Vyas, V. K., & Ghate, M. D. (2021). Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders. *European Journal of Medicinal Chemistry*, 216(113332), 113332.
- Giess, D., Erdos, J., & Wild, C. (2024). An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. *European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society*, 51, 84–92.
- Groen, E. J. N., Talbot, K., & Gillingwater, T. H. (2018). Advances in therapy for spinal muscular atrophy: promises and challenges. *Nature Reviews. Neurology*, 14(4), 214–224.
- Harding, B. N., Kariya, S., Monani, U. R., Chung, W. K., Benton, M., Yum, S. W., Tennekoon, G., & Finkel, R. S. (2015). Spectrum of neuropathophysiology in spinal muscular atrophy type I. *Journal of Neuropathology and Experimental Neurology*, 74(1), 15–24.
- Hofman, F. M., & Taylor, C. R. (2013). Immunohistochemistry. *Current Protocols in Immunology*, 103(1), 21.4.1–21.4.26.
- Hou, D., Liao, H., Hao, S., Liu, R., Huang, H., & Duan, C. (2024). Curcumin simultaneously improves mitochondrial dynamics and myocardial cell bioenergy after sepsis via the SIRT1-DRP1/PGC-1 $\alpha$  pathway. *Heliyon*, 10(7), e28501.
- Im, K., Mareninov, S., Diaz, M. F. P., & Yong, W. H. (2019). An introduction to performing immunofluorescence staining. *Methods in Molecular Biology (Clifton, N.J.)*, 1897, 299–311.
- James, R., Chaytow, H., Ledahawsky, L. M., & Gillingwater, T. H. (2021). Revisiting the role of mitochondria in spinal muscular atrophy. *Cellular and Molecular Life Sciences*, 78(10), 4785–4804.
- Keinath, M. C., Prior, D. E., & Prior, T. W. (2021). Spinal muscular atrophy: Mutations, testing, and clinical relevance. *The Application of Clinical Genetics*, 14, 11–25.
- Kholifah, E., & Endah, E. (2022). Analisis Profil Fisika Kimia dan Farmakokinetik Senyawa Pentagamavunon-1 Secara Komputasi. *Duta Pharma Journal*, 2(1), 1–7.

- Kobayashi, D. T., Olson, R. J., Sly, L., Swanson, C. J., Chung, B., Naryshkin, N., Narasimhan, J., Bhattacharyya, A., Mullenix, M., & Chen, K. S. (2011). Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. *PloS One*, *6*(8), e24269.
- Kolb, S. J., & Kissel, J. T. (2015). Spinal muscular atrophy. *Neurologic Clinics*, *33*(4), 831–846.
- Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., & Zeviani, M. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. *Cell*, *80*(1), 155–165.
- Lefebvre, S., Burlet, P., Liu, Q., Bertrand, S., Clermont, O., Munnich, A., Dreyfuss, G., & Melki, J. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. *Nature Genetics*, *16*(3), 265–269.
- Lestari, B., Nakamae, I., Yoneda-Kato, N., Morimoto, T., Kanaya, S., Yokoyama, T., Shionyu, M., Shirai, T., Meiyanto, E., & Kato, J.-Y. (2019). Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. *Scientific Reports*, *9*(1), 14867.
- Li, X., Zhu, J., Lin, Q., Yu, M., Lu, J., Feng, J., & Hu, C. (2022). Effects of curcumin on mitochondrial function, endoplasmic reticulum stress, and mitochondria-associated endoplasmic reticulum membranes in the jejunum of oxidative stress piglets. *Journal of Agricultural and Food Chemistry*, *70*(29), 8974–8985.
- Lin, J., & Alcocer, M. (Eds.). (2017). *Food allergens*. Humana Press.
- Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006). Multiple biological activities of curcumin: a short review. *Life Sciences*, *78*(18), 2081–2087.
- Marasco, L. E., Dujardin, G., Sousa-Luís, R., Liu, Y. H., Stigliano, J. N., Nomakuchi, T., Proudfoot, N. J., Krainer, A. R., & Kornblihtt, A. R. (2022). Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. *Cell*, *185*(12), 2057–2070.e15.
- Meiyanto, E., Putri, H., Arum Larasati, Y., Yudi Utomo, R., Istighfari Jenie, R., Ikawati, M., Lestari, B., Yoneda-Kato, N., Nakamae, I., Kawaichi, M., & Kato, J.-Y. (2019). Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. *Advanced Pharmaceutical Bulletin*, *9*(3), 445–452.
- Mishra, N. K., & Mishra, A. (2025). Spinal Muscular Atrophy (SMA): Treatment strategies, challenges and future prospects. *Pharmacological Research - Reports*, *3*(100031), 100031.
- Nurputra, D. K., Lai, P. S., Harahap, N. I. F., Morikawa, S., Yamamoto, T., Nishimura, N., Kubo, Y., Takeuchi, A., Saito, T., Takeshima, Y., Tohyama, Y., Tay, S. K. H., Low, P. S., Saito, K., & Nishio, H. (2013). Spinal muscular atrophy: from gene discovery to clinical trials. *Annals of Human Genetics*, *77*(5), 435–463.

- Osellame, L. D., Blacker, T. S., & Duchen, M. R. (2012). Cellular and molecular mechanisms of mitochondrial function. *Best Practice & Research. Clinical Endocrinology & Metabolism*, 26(6), 711–723.
- Pagliarini, V., Guerra, M., Di Rosa, V., Compagnucci, C., & Sette, C. (2020). Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. *Journal of Neurochemistry*, 153(2), 264–275.
- Park, G., Kim, S. S., Shim, J., & Lee, S.-J. V. (2025). Brief guide to immunostaining. *Molecules and Cells*, 48(1), 100157.
- Perdana, I., Yuniarti, N., & Puspitasari, I. (2025). Uji Toksisitas Akut Sediaan SNEDDS Pentagamavunon-0 pada Mencit Betina BALB/c. *Majalah Farmaseutik*, 21(2), 221.
- Pierzchlewicz, K., Kępa, I., Podogrodzki, J., & Kotulska, K. (2021). Spinal muscular atrophy: The use of functional motor scales in the era of disease-modifying treatment. *Child Neurology Open*, 8, 2329048X211008725.
- Piña, R., Santos-Díaz, A. I., Orta-Salazar, E., Aguilar-Vazquez, A. R., Mantellero, C. A., Acosta-Galeana, I., Estrada-Mondragon, A., Prior-Gonzalez, M., Martinez-Cruz, J. I., & Rosas-Arellano, A. (2022). Ten approaches that improve immunostaining: A review of the latest advances for the optimization of immunofluorescence. *International Journal of Molecular Sciences*, 23(3), 1426.
- Plikus, M. V., Wang, X., Sinha, S., Forte, E., Thompson, S. M., Herzog, E. L., Driskell, R. R., Rosenthal, N., Biernaskie, J., & Horsley, V. (2021). Fibroblasts: Origins, definitions, and functions in health and disease. *Cell*, 184(15), 3852–3872.
- Prior, T. W., & Nagan, N. (2016). Spinal muscular atrophy: Overview of molecular diagnostic approaches. *Current Protocols in Human Genetics*, 88(1), 9.27.1-9.27.13.
- Protasoni, M., & Zeviani, M. (2021). Mitochondrial structure and bioenergetics in normal and disease conditions. *International Journal of Molecular Sciences*, 22(2), 586.
- Rahmawati, D. R., Nurrochmad, A., Jenie, R. I., & Meiyanto, E. (2023). The synergistic cytotoxic effect of pentagamavunon-1 (PGV-1) and curcumin correlates with the cell cycle arrest to induce mitotic catastrophe in 4T1 and T47D breast cancer cells. *The Indonesian Biomedical Journal*, 15(5), 318–327.
- Ripolone, M., Ronchi, D., Violano, R., Vallejo, D., Fagiolari, G., Barca, E., Lucchini, V., Colombo, I., Villa, L., Berardinelli, A., Balottin, U., Morandi, L., Mora, M., Bordoni, A., Fortunato, F., Corti, S., Parisi, D., Toscano, A., Sciacco, M., ... Moggio, M. (2015). Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. *JAMA Neurology*, 72(6), 666–675.
- Rossoll, W., Jablonka, S., Andreassi, C., Kröning, A.-K., Karle, K., Monani, U. R., & Sendtner, M. (2003). Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in

- growth cones of motoneurons. *The Journal of Cell Biology*, 163(4), 801–812.
- Sakla, M. S., & Lorson, C. L. (2008). Induction of full-length survival motor neuron by polyphenol botanical compounds. *Human Genetics*, 122(6), 635–643.
- Sathyabhama, M., Priya Dharshini, L. C., Karthikeyan, A., Kalaiselvi, S., & Min, T. (2022). The credible role of curcumin in oxidative stress-mediated mitochondrial dysfunction in mammals. *Biomolecules*, 12(10), 1405.
- Schleiff, E., & Turnbull, J. L. (1998). Functional and structural properties of the mitochondrial outer membrane receptor Tom20. *Biochemistry*, 37(38), 13043–13051.
- Schorling, D. C., Pechmann, A., & Kirschner, J. (2020). Advances in treatment of spinal Muscular Atrophy - new phenotypes, new challenges, new implications for care. *Journal of Neuromuscular Diseases*, 7(1), 1–13.
- Shah, K., & Maghsoudlou, P. (2016). Enzyme-linked immunosorbent assay (ELISA): the basics. *British Journal of Hospital Medicine (London, England: 2005)*, 77(7), C98-101.
- Sierra-Delgado, J. A., Sinha-Ray, S., Kaleem, A., Ganjibakhsh, M., Parvate, M., Powers, S., Zhang, X., Likhite, S., & Meyer, K. (2023). In vitro modeling as a tool for testing therapeutics for Spinal Muscular Atrophy and IGHMBP2-related disorders. *Biology*, 12(6), 867.
- Signoria, I., Zwartkruis, M. M., Geerlofs, L., Perenthaler, E., Faller, K. M. E., James, R., McHale-Owen, H., Green, J. W., Kortooms, J., Snellen, S. H., Asselman, F.-L., Gillingwater, T. H., Viero, G., Wadman, R. I., van der Pol, W. L., & Groen, E. J. N. (2024). Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts. *Molecular Therapy. Methods & Clinical Development*, 32(4), 101379.
- Singh, R. N., Howell, M. D., Ottesen, E. W., & Singh, N. N. (2017). Diverse role of survival motor neuron protein. *Biochimica et Biophysica Acta. Gene Regulatory Mechanisms*, 1860(3), 299–315.
- Soflaei, S. S., Momtazi-Borojeni, A. A., Majeed, M., Derosa, G., Maffioli, P., & Sahebkar, A. (2018). Curcumin: A natural pan-HDAC inhibitor in cancer. *Current Pharmaceutical Design*, 24(2), 123–129.
- Starkov, A. A. (2008). The role of mitochondria in reactive oxygen species metabolism and signaling. *Annals of the New York Academy of Sciences*, 1147(1), 37–52.
- Sukswai, N., & Khoury, J. D. (2019). Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection. *Current Hematologic Malignancy Reports*, 14(5), 368–375.
- Tirichen, H., Yaigoub, H., Xu, W., Wu, C., Li, R., & Li, Y. (2021). Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. *Frontiers in Physiology*, 12, 627837.
- Vincent, A. E., Ng, Y. S., White, K., Davey, T., Mannella, C., Falkous, G., Feeney, C., Schaefer, A. M., McFarland, R., Gorman, G. S., Taylor, R. W., Turnbull, D. M., & Picard, M. (2016). The spectrum of mitochondrial ultrastructural defects in mitochondrial myopathy. *Scientific Reports*, 6, 30610.

- Wadman, R. I., Stam, M., Jansen, M. D., van der Weegen, Y., Wijngaarde, C. A., Harschnitz, O., Soodaar, P., Braun, K. P. J., Dooijes, D., Lemmink, H. H., van den Berg, L. H., & van der Pol, W. L. (2016). A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls. *PloS One*, *11*(11), e0167087.
- Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., Trela, A., & Participants of the International Conference on SMA Standard of Care. (2007). Consensus statement for standard of care in spinal muscular atrophy. *Journal of Child Neurology*, *22*(8), 1027–1049.
- Wirth, B. (2021). Spinal muscular atrophy: In the challenge lies a solution. *Trends in Neurosciences*, *44*(4), 306–322.
- Yang, S., Yu, H., Xu, J., Wu, C., Cheng, Y., Tian, M., Ding, Y., Yang, Y., Chen, Z., Lv, M., Sun, J., Lin, Y., Zhang, K., Liu, X., Guo, Y., Zhang, L., Fang, J., & Lai, B. (2025). Neural network tissue and myocytes co-culture system reveals effects of different myocytes on postnatal development of spinal cord neural network. *Cellular and Molecular Life Sciences*, *82*(1), 378.
- Zhao, T., Xue, Y., Bai, M.-S., Dong, H.-Y., & Jia, F.-Y. (2025). Clinical application of Risdiplam in 5q spinal muscular atrophy: A narrative review. *British Journal of Hospital Medicine (London, England: 2005)*, *86*(4), 1–25.
- Zilio, E., Piano, V., & Wirth, B. (2022). Mitochondrial dysfunction in spinal muscular atrophy. *International Journal of Molecular Sciences*, *23*(18), 10878.
- Zorova, L. D., Popkov, V. A., Plotnikov, E. Y., Silachev, D. N., Pevzner, I. B., Jankauskas, S. S., Babenko, V. A., Zorov, S. D., Balakireva, A. V., Juhaszova, M., Sollott, S. J., & Zorov, D. B. (2018). Mitochondrial membrane potential. *Analytical Biochemistry*, *552*, 50–59.